Division of Gastroenterology (Liver Unit), University of Alberta, Edmonton, AB, Canada.
Division of Gastroenterology and Hepatology, University of Calgary, Calgary, AB, Canada.
Hepatology. 2021 Dec;74(6):3301-3315. doi: 10.1002/hep.32033. Epub 2021 Aug 15.
Portal hypertension (PH) is a major driver for cirrhosis complications. Portal pressure is estimated in practice by the HVPG. The assessment of HVPG changes has been used for drug development in PH. This study aimed at quantifying the test-retest reliability and consistency of HVPG in the specific context of randomized controlled trials (RCTs) for the treatment of PH in cirrhosis and its impact on power calculations for trial design.
We conducted a search of published RCTs in patients with cirrhosis reporting individual patient-level data of HVPG at baseline and after an intervention, which included a placebo or an untreated control arm. Baseline and follow-up HVPGs in the control groups were extracted after digitizing the plots. We assessed reliability and consistency and the potential impact of study characteristics. We retrieved a total of 289 before and after HVPG measurements in the placebo/untreated groups from 20 RCTs. The time span between the two HVPG measurements ranged between 20 minutes and 730 days. Pre-/post-HVPG variability was lower in studies including only compensated patients; therefore, modeled sample size calculations for trials in compensated cirrhosis were lower than for decompensated cirrhosis. A higher proportion of alcohol-associated cirrhosis and unicentric trials was associated with lower differences between baseline and follow-up measurements. The smallest detectable difference in an individual was 26% and 30% in compensated and decompensated patients, respectively.
The test-retest reliability of HVPG is overall excellent. Within-individual variance was higher in studies including higher proportions of decompensated patients. These findings should be taken into account when performing power analysis for trials based on the effects on HVPG or when considering HVPG as a tool to guide therapy of PH.
门静脉高压症(PH)是肝硬化并发症的主要驱动因素。门静脉压力在实践中通过 HVPG 进行估计。HVPG 变化的评估已用于 PH 的药物开发。本研究旨在量化 HVPG 在肝硬化 PH 治疗的随机对照试验(RCT)中的具体情况下的复测可靠性和一致性,及其对试验设计的效力计算的影响。
我们对发表的 RCT 进行了检索,这些 RCT 报告了基线和干预后 HVPG 的个体患者水平数据,包括安慰剂或未治疗的对照组。在对图表进行数字化后,我们提取了对照组的基线和随访 HVPG。我们评估了可靠性和一致性以及研究特征的潜在影响。我们从 20 项 RCT 中总共检索到 289 项安慰剂/未治疗组的 HVPG 前后测量值。两次 HVPG 测量之间的时间间隔在 20 分钟到 730 天之间。仅包括代偿性患者的研究中,HVPG 的前后变异性较低;因此,代偿性肝硬化试验的模型样本量计算值低于失代偿性肝硬化。更高比例的酒精相关性肝硬化和单中心试验与基线和随访测量值之间的差异较低相关。个体患者的最小可检测差异分别为代偿性和失代偿性患者的 26%和 30%。
HVPG 的复测可靠性总体上非常好。包括更多失代偿患者的研究中个体内变异性更高。在基于 HVPG 效应进行效力分析或考虑 HVPG 作为指导 PH 治疗的工具时,应考虑到这些发现。